211 related articles for article (PubMed ID: 28726049)
1. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
3. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
Guerzoni S; Pellesi L; Baraldi C; Pini LA
J Headache Pain; 2015; 17():48. PubMed ID: 27146068
[TBL] [Abstract][Full Text] [Related]
4. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Negro A; Curto M; Lionetto L; Martelletti P
J Headache Pain; 2015; 17():1. PubMed ID: 26792662
[TBL] [Abstract][Full Text] [Related]
5. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
[TBL] [Abstract][Full Text] [Related]
6. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy.
Santoro A; Copetti M; Miscio AM; Leone MA; Fontana A
Neurol Sci; 2020 Jul; 41(7):1809-1820. PubMed ID: 32052306
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
9. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
[TBL] [Abstract][Full Text] [Related]
10. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
11. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
12. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
[TBL] [Abstract][Full Text] [Related]
13. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
14. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
15. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT; Jaffri SF
Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
[TBL] [Abstract][Full Text] [Related]
16. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
Khalil M; Zafar HW; Quarshie V; Ahmed F
J Headache Pain; 2014 Sep; 15(1):54. PubMed ID: 25178393
[TBL] [Abstract][Full Text] [Related]
17. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
[TBL] [Abstract][Full Text] [Related]
18. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
[TBL] [Abstract][Full Text] [Related]
19. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
[TBL] [Abstract][Full Text] [Related]
20. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
Blumenfeld AM; Aurora SK; Laranjo K; Papapetropoulos S
BMC Neurol; 2015 Jul; 15():100. PubMed ID: 26133547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]